New study opens door for CAR t therapy in patients with kidney disease
NCT ID NCT05909059
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at whether CAR T cell therapy, a type of cancer treatment that uses a patient's own immune cells, can be safely given to people with moderate to severe kidney problems. The trial involves 20 adults with blood cancers like lymphoma, myeloma, or leukemia. Before getting the CAR T cells, patients receive a lower dose of chemotherapy to prepare their bodies, and researchers will monitor side effects such as immune reactions and low blood counts.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Fludarabine and cyclophosphamide chemotherapy before CAR T cell therapy
- What this could lead to
- If successful, this could show that CAR T therapy is safe and feasible for patients with kidney problems, expanding treatment options for this group.
- What could go wrong
- This is a small, early-phase study with only 20 participants, so results may not apply broadly. There are risks of serious side effects like cytokine release syndrome and low blood counts.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA, ADULT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Caitlin Guzowski
RECRUITINGAtlanta, Georgia, 30342, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could muscle loss predict blood cancer outcomes?
- Can a Triple-Action antibody deepen remissions in myeloma?
- Can a Tumor's DNA guide better cancer care for kids?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Can engineered immune cells tackle brain lymphoma?